The U.S. Food and Drug Administration has approved asundexian, sold under the brand name Sunharbo, as the first medicine in the factor XIa inhibitor class. The approval creates a new option for secondary stroke prevention, but only for a clearly defined group of adults and only in combination with antiplatelet therapy.
Who the approval covers
The FDA indication is for adults who have recently had a mild-to-moderate non-cardioembolic ischemic stroke or a high-risk transient ischemic attack (TIA). “Non-cardioembolic” means the clot was not judged to have originated in the heart. The medicine is not approved for stroke prevention in people with atrial fibrillation.
That distinction is essential. Stroke prevention is not one treatment pathway: the cause of the event, imaging findings, heart rhythm, bleeding risk, liver function and other medicines can all change the recommended approach. Asundexian is not a substitute for an individualized post-stroke plan.
What the pivotal study found
The approval was based on OCEANIC-STROKE, a randomized, double-blind, placebo-controlled phase 3 study of 12,327 adults. Participants entered the study within 72 hours of a recent qualifying stroke or high-risk TIA. Both groups received antiplatelet therapy; one group also received asundexian 50 mg once daily and the other received placebo.
According to the FDA, asundexian reduced the relative risk of ischemic stroke by 26% over a median follow-up of 14.2 months. A relative reduction does not tell an individual patient exactly how much their personal risk changes. That depends on their starting risk and clinical profile, so the result should be interpreted with a treating team rather than used as a stand-alone number.
Why factor XIa is a different target
Factor XIa participates in the amplification of thrombin generation, part of the clotting process. Researchers have studied whether inhibiting this pathway can reduce pathological clot formation while preserving more of normal hemostasis than some established anticoagulant strategies. The FDA approval shows that the approach can provide clinical benefit in this specific post-stroke population, but it does not remove bleeding risk.
Bleeding and other safety considerations
The overall rate of major bleeding in the trial was similar between the asundexian and placebo groups, the FDA reported. However, major bleeding was increased among participants older than 75 and during the first 90 days of treatment. Gastrointestinal bleeding occurred more often with asundexian. Diarrhea was the most frequently reported adverse reaction occurring in at least 3% of treated participants.
The agency also highlighted several practical cautions:
- Combined P-glycoprotein and strong CYP3A4 inducers, including carbamazepine, may reduce the medicine’s effectiveness and are not recommended with it.
- Asundexian is not recommended in moderate or severe hepatic impairment.
- It should be withheld for at least 24 hours before elective surgery or an invasive procedure.
- It should also be withheld for at least 24 hours after thrombolysis for an acute ischemic stroke.
Patients should not start, stop or pause an antithrombotic medicine without direct clinical instructions. Sudden changes can increase either clotting or bleeding risk.
What this means outside the United States
This is a U.S. regulatory decision. Approval, availability and prescribing information may differ in other countries. Patients in Europe or elsewhere should not assume that a U.S. approval means the medicine is locally authorized or available.
The larger picture after a stroke or TIA
Medication is only one part of secondary prevention. Blood-pressure management, lipid treatment, diabetes care, smoking cessation, physical activity when medically appropriate, and investigation of the event’s cause remain central. Follow-up is especially important soon after a TIA or stroke, when recurrence risk can be high.
Asundexian’s approval is scientifically important because it validates a new drug class. Clinically, its significance will depend on careful patient selection, attention to bleeding and interactions, and integration with established post-stroke care—not on treating it as a universal replacement for existing therapies.
Source: U.S. Food and Drug Administration approval announcement, November 9, 2026.
Featured image: Online Marketing / Unsplash. Illustrative only.
